Specialty Pharmacy

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses which drugs are expected to dominate the market in 2017.

Top news of the day from across the health care landscape.

Paclitaxel plus nintedanib overcomes chemotherapy-resistance in endometrial cancer.

Top news of the week from Specialty Pharmacy Times.

Jon Gavras, MD, chief medical officer at Prime Therapeutics, lists the strategies pharmacy benefit managers use to reduce spending on opioids.

Inhibiting a protein kinase may improve the efficacy of radiation in glioblastoma.

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

If one-quarter of HIV-negative patients took PrEP, a significant amount of new HIV infections could be prevented.

Treatment with hydroxyurea increased hemoglobin F levels for patients with sickle cell anemia.

Nivolumab (Opdivo) showed better tolerability than ipilimumab (Yervoy) in patients with metastatic melanoma.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Top news of the day from across the health care landscape.

Priority areas that pharmacists should focus on ahead of USP .

Cabozantinib (Cabometyx) was previously granted priority review as a therapy for advanced renal cell carcinoma.

Bosutinib (Bosulif) was approved by the FDA to treat patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.

Trastuzumab (Herceptin) is indicated to treat HER2+ breast and gastric cancers.

Patients treated with chemotherapy biweekly were 17% less likely to experience breast cancer recurrence over 10 years.

Elvin Montanez, PharmD, chief operations officer at BioPlus Specialty Pharmacy, discusses the importance of a quick turnaround from patient referral to acceptance.

Human Vaccines Project seeks to decode the human immune system to facilitate accelerated development of diagnostics, vaccines and therapies for major global diseases.

Top news of the day from across the health care landscape.

Luxturna (voretigene neparvovec-rzyl) is indicated to treat confirmed biallelic RPE65 mutation-associated retinal dystrophy.

The average profit from cancer drugs administered by 340B hospitals was nearly 50% in 2015.

CAR T cell therapy resulted in a high response rate among previously-treated patients with multiple myeloma.

Polatuzumab vedotin plus bendamustine and rituximab increased complete response rates to 40% among patients with diffuse large B-cell lymphoma.

Top news of the day from across the health care landscape.

Fingolimod was previously approved to treat relapsing multiple sclerosis as a once-daily disease-modifying therapy.

Marc O’Connor, chief operating officer at Curant Health, explains ways patient care models can reduce costs.

Multiple specialty pharmacy processes can delay the time-to-fill for specialty medications.